Brussels (ots/PRNewswire) - · Revenue increased to EUR 5.3 billion (+9%, +8% CER[1]) net sales to EUR 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was EUR 1.4 billion (+1%, -4% CER) or 27% of revenue · R&D update: bimekizumab filed with FDA and EMA for psoriasis; timelines for late stage pipeline confirmed - despite pandemic · Financial ...
Brussels and Atlanta (ots/PRNewswire) - - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI technology and applied scientists to work alongside UCB's scientists and data specialists, aiming to allow UCB to discover new correlations ...
Brussels, Belgium (ots/PRNewswire) - - Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis - Advantage Hers will equip and empower women around the world living with chronic inflammatory diseases, ...
Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...
Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...
Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...
Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...
Brussels (ots/PRNewswire) - - Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 - Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic - No physical presence at General Meeting allowed and votes can only be submitted by ...
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...
Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised3 - Specialists (82%) believe osteoporosis is a silent epidemic, yet only 24% believe their healthcare system is ...
Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...
Brussels (ots/PRNewswire) - - NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa - NEUPRO approval in China reinforces UCB's ongoing commitment to supporting patient value across China and to offering Chinese patients additional ...
Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...
Brussels and Geneva (ots/PRNewswire) - - Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world - Groups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the Resolution on ...
Atlanta and Brussels (ots/PRNewswire) - - BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures - Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic ...
Brussels (ots/PRNewswire) - Strictly not for UK/Irish media - CIMZIA® (certolizumab pegol) Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologic-naïve and previously treated patients, with clinical benefit maintained up to one year[1] - This milestone represents UCB's ...
Brussels (ots/PRNewswire) - - Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug ...
Brussels (ots/PRNewswire) - - Acquisition to strengthen UCB's genomics and epigenomics research platform to identify novel drug targets UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). The total cost of the transaction, ...
Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding - Data submitted to regulatory authorities included ...
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
Brussels, Belgium (ots/PRNewswire) - The Excellence in Epilepsy Journalism Award, a joint initiative of the International Bureau for Epilepsy (IBE) and UCB, recognizes and rewards journalists from across the world who produce informed and compelling news and feature stories on epilepsy, as decided by an independent, international judging panel. Articles and ...
Brussels, Belgium, March 19, 2010 (ots/PRNewswire) - Patients with neurological diseases need more help with their associated sleep-wake disturbances that can often make their underlying illness worse, say leading sleep specialists attending a sleep meeting hosted by biopharmaceutical company, UCB, to mark World ...